The Architect Of Biogen's Controversial Alzheimer's Strategy, Al Sandrock, To Retire
Executive Summary
Despite 23 years at Biogen assisting in the development of several drugs, Sandrock's legacy will be tied to Alzheimer’s drug Aduhelm.
You may also be interested in...
Biogen’s Latest Leadership Change Hints At Immunology Ambitions
New head of research Jane Grogan comes to Biogen from start-ups Graphite Bio and ArsenalBio, and previously held leadership positions in autoimmune and oncology R&D at Genentech.
Biogen’s Adam Keeney Focuses On Dealmaking As Growth Strategy Is Made Over
Recently appointed head of corporate development in an ongoing leadership shakeup, Keeney is helping to shape Biogen’s sustainable growth strategy in neuroscience and beyond.
Biogen’s Pipeline: Alzheimer’s Is In, Stroke Is Out
The company is prioritizing investment in the launches of Leqembi, zuranolone and newly approved Qalsody as well as key pipeline assets, while discontinuing investment in two stroke programs.